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Abstract
Hyperthermia is a predictor of poor outcome in ischemic (IS) and intracerebral hemorrhagic (ICH) stroke. Our aim was to
study the plausible mechanisms involved in the poor outcome associated to hyperthermia in stroke. We conducted a case-
control study including patients with IS (n = 100) and ICH (n = 100) within the first 12 hours from symptom onset.
Specifically, IS and ICH patients were consecutively included into 2 subgroups, according to the highest body temperature
within the first 24 hours: Tmax ,37.5uC and Tmax $37.5uC, up to reach 50 patients per subgroup of temperature for both
IS and ICH patients. Body temperature was determined at admission and every 4 hours during the first 48 hours. Main
outcome variable was poor functional outcome (modified Rankin scale score .2) at 3 months. Serum levels of glutamate
and active MMP-9 were measured at admission. Our results showed that Tmax $37.5uC within the first 24 hours was
independently associated with poor outcome in both IS (OR, 12.43; 95% CI, 3.73–41.48; p,0.0001) and ICH (OR, 4.29; 95% CI,
1.32–13.91; p = 0.015) after adjusting for variables with a proven biological relevance for outcome. However, when
molecular markers levels were included in the logistic regression model, we observed that glutamate (OR, 1.01; 95% CI,
1.00–1.02; p = 0.001) and infarct volume (OR, 1.06; 95% CI, 1.01–1.10; p = 0.015) were the only variables independently
associated to poor outcome in IS, and active MMP-9 (OR, 1.04; 95% CI, 1.00–1.08; p = 0.002) and National Institute of Health
Stroke Scale (NIHSS) at admission (OR, 1.29; 95% CI, 1.13–1.49; p,0.0001) in ICH. In conclusion, these results suggest that
although the outcome associated to hyperthermia is similar in human IS and ICH, the underlying mechanisms may be
different.
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Introduction
Demographic changes and improvement in quality of health
care systems in developed countries are conditioning an increase in
the incidence and prevalence of ischemic stroke (IS) and
intracerebral hemorrhage (ICH). Therefore understand the
molecular mechanisms involved in both neurological pathologies
in order to find new and more efficient treatments are highly
demanded.
Pharmacological (intravenous or intra-arterial) or mechanical
reperfusion therapies are the only approved treatment during the
acute phase of IS; however this treatment it is difficult to apply in
more than 10% of patients due to its short therapeutic window and
secondary complications [1]. In case of ICH, no satisfactory
pharmacological treatments have been developed against this
disorder with high mortality and poor prognosis rates [2].
Standard management for ICH is principally supportive, including
airway protection, maintenance of hemodynamic stability, and
control of intracranial pressure. In addition, it is well described
that extravasation of blood molecular mediators into brain
parenchyma after ICH mediates hematoma growth, edema and
cell death. Therefore, early administration of hemostatic agents,
meticulous blood pressure control, early surgical evacuation, and
catheter hematoma aspiration have also been tried without success
to limit hematoma expansion [3].
In both IS and ICH, hyperthermia is a common complication
that occurs in up to 30–40% of patients, and it is independently
associated with poor outcome and increased mortality [4–9].
However, although the molecular mechanisms underlying the
deleterious effect of hyperthermia in IS is reasonably well
described in ICH is largely unknown. Previous studies by our
group, performed in animal models of cerebral ischemia, have
demonstrated that the deleterious effect of hyperthermia is
mediated mainly through the increase of glutamate excitotoxicity,
while the protective effect associated to hypothermic treatments is
tightly associated with a reduction of glutamate release [10], being
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these data also in agreement with our previous clinical data [11].
On the other hand, glutamate release seems to act as an important
secondary mechanism of injury following hematoma growth in
ICH [2]. In this regard, it was demonstrated in animal models of
ICH that a transient elevation of the extracellular concentration of
glutamate in the perihematomal region appears after hematoma
formation. Likewise, memantine treatment, a low-affinity blocker
of the N-methyl-D-aspartate subtype of glutamate receptor–
associated channels, reduced hemorrhage volume, apoptotic cell
death, neutrophil infiltration, and the number of microglia/
macrophages in the periphery of hematoma [12,13]. However, it is
still largely unknown if glutamate excitotoxicity plays a critical role
in the effect of hyperthermia during ICH.
Due to the adverse effect of hyperthermia in both IS and ICH
outcome, our aim was to study whether glutamate release acts as a
key molecular mechanism involved in the poor outcome associated
to hyperthermia in human IS and ICH.
Methods
Study population
This is a case-control study including patients with IS (n = 100)
and ICH (n = 100) within the first 12 hours from symptom onset.
Specifically, IS and ICH patients were consecutively included into
2 subgroups, according to the highest body temperature within the
first 24 hours: Tmax ,37.5uC and Tmax $37.5uC, up to reach
50 patients per subgroup of temperature for both IS and ICH
patients. Recruitment period was from April 2009 to July 2012.
The study was carried out in accordance with the Declaration of
Helsinki of the World Medical Association (2008) and approved by
the Ethics Committee of Clinical Research of Galicia (CEIC).
Written informed consent was obtained from each patient or their
relatives after full explanation of the procedures.
According to the classification used in previous studies [14,15],
admission axillary temperature $37.5uC was considered as
hyperthermia (independently of fever), whereas axillary tempera-
ture ,37.5uC was considered as normothermia.
Following the clinical protocol of the stroke unit of our hospital,
patients with axillary temperature $37.5uC were treated with
metamizol (2 g intravenous) or paracetamol (500 mg orally) every
6 hours (although treatment with metamizol and paracetamol
were used to control hyperthermia, the condition of hypothermia
was not induced in any of the patients recruited).
Sample size for the present study was calculated using the
statistical EPIDAT software (y, based on a prevalence of poor
outcome .35% in stroke patients with hyperthermia according to
previous studies [9,15]. The minimum sample size calculated to
detect this effect was made accepting an alpha level of 5% and a
power of 80%.
This research was carried out in accordance with the
Declaration of Helsinki of the World Medical Association (2008)
and approved by the Ethics Committee of Clinical Research of
Galicia (CEIC). Informed consent was obtained from each patient
or their relatives after full explanation of the procedures.
Clinical and neuroimaging variables
All patients were admitted in the acute stroke unit and handled
by the same stroke team according to the Stroke Unit protocol of
the Hospital Clı́nico Universitario de Santiago de Compostela.
Medical history recording potential vascular risk factors, blood
and coagulation tests, 12-lead ECG, chest x-ray, and carotid
ultrasonography were performed at admission.
In accordance with previous clinical studies [7] and following
the Stroke Unit protocol of our hospital, axillary temperatures
were measured by nurses. Temperature was obtained at admission
and every 4 hours during the first 48 hours. Basal temperature
and the highest temperature within the first 24 were considered for
the analysis.
Stroke subtype was classified according to the TOAST criteria
[16] in IS and as hypertensive, amyloid, in relation to antiplatelet/
anticoagulant treatment, and secondary to arteriovenous malfor-
mation or others in ICH.
Stroke severity was assessed by an internationally certified
neurologist using the National Institute of Health Stroke Scale
(NIHSS) at admission, 24, 48 and 72 hours. Early neurological
deterioration (END) was defined as an increase $4 points in
NIHSS within the first 72 hours with respect to baseline NIHSS
score. Functional outcome was evaluated at 3 months and poor
functional outcome, the main outcome variable of the study, was
defined as a modified Rankin Scale (mRS) score .2.
The use of reperfusion therapy, the inclusion in clinical trials
and the presence of infections during the first 72 hours were also
considered for the analysis.
All patients underwent cranial computed tomography (CT) at
admission as well as a control CT between days 4 and 7. In
patients with IS, a multimodal MRI (magnetic resonance imaging)
was also performed at admission. Lesion volumes were measured
using ABC/2 method [17] in DWI-MRI and control CT in
patients with IS, and in CT at admission and control CT in
patients with ICH. Neuroradiologists blinded to clinical and
analytical data performed all imaging studies.
Laboratory tests
Blood samples, obtained from all patients at admission were
collected in chemistry test tubes, centrifuged at 3000 g for 15
minutes, and immediately frozen and stored at 280uC. Serum
levels of Glu were determined by high performance liquid
chromatography (HPLC) analysis following a previously described
method [18], while active matrix metalloprotease- 9 (MMP-9)
levels (GE Healthcare - Amersham, Little Chalfont Buckingham-
shire,UK) were measured using commercial ELISA kits following
manufacturer instructions. The intra-assay and inter-assay coeffi-
cients of variation were 1.7% and 2.3% for Glu, and 3.6% and
6.6% for active MMP-9, respectively. Determinations were
performed in an independent laboratory blinded to clinical data.
Statistical Analysis
Results were expressed as percentages for categorical variables
and as mean (SD) or median and range (25th and 75th percentiles)
for the continuous variables depending on whether their
distribution was normal or not. The Kolmogorov-Smirnov test
was used for testing the normality of the distribution. Proportions
were compared using the chi-square or Fisher test, while the
continuous variables between groups were compared with the
Student’s t or the Mann-Whitney tests. Spearman’s or Pearson’s
analyses were used for bivariate correlations. ANOVA was used
for comparison among several quantitative variables. The
influence of molecular marker levels and temperature on poor
functional outcome at 3 months was assessed by logistic regression
analysis after adjusting for those variables with a proven biological
relevance for outcome to avoid the possibility of finding some
spurious associations, and that the effect of some predictors on the
endpoint was not masked by the effect of some confounders.
Specifically, the preselected outcome confounders for IS were age,
history of atrial fibrillation, NIHSS at admission, glucose levels
and DWI volume at admission [7]; while age, previous anticoag-
ulants, history of hypertension, NIHSS and ICH volume at
admission were preselected for ICH [6]. Results were expressed as
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adjusted odds ratios (OR) with the corresponding 95% confidence
intervals (95% CI). The results of the OR corresponding to each
unit of the corresponding variable (for example, per unit of
NIHSS, per mL of DWI volume, per ng of MMP-9, per mM of
glutamate, etc.). The statistical analysis was conducted using SPSS
16.0 (SPSS Inc. Chicago, IL, USA).
Results
Table 1 shows clinical, biochemical and neuroimaging
characteristics of IS and ICH patients classified according to the
cutoff of point of Tmax ,37.5uC or Tmax $37.5uC for the
highest body temperature within the first 24 hours. All groups
were comparable regarding clinical characteristics, pharmacolog-
ical treatments and IS or ICH subtype. However, both IS and
ICH patients with Tmax $37.5uC showed worse functional
outcome at 3 months, larger infarct or ICH volumes at 4th-7th day
as well as larger infarct or ICH growth, and increased frequency of
infections. Furthermore, IS patients with Tmax $37.5uC showed
higher levels of glucose, fibrinogen, high-sensitivity C-reactive
protein (hs-CRP) and leukocytes, while ICH patients with Tmax
$37.5uC had increased frequency of END. Regarding molecular
markers, IS patients with Tmax $37.5uC showed higher levels of
Glu. By contrast, ICH patients with Tmax $37.5uC showed
higher levels of active MMP-9. In fact, we found strong
correlations between Glu levels at admission and the highest body
temperature within the first 24 hours (r = 0.458, p,0.0001) for IS
patients, and between active MMP-9 levels at admission and the
highest body temperature within the first 24 hours (r = 0.654,
p,0.0001) for ICH patients.
In the multivariate analysis, Tmax $37.5uC within the first
24 hours was independently associated with poor outcome in both
IS (OR, 12.43; 95% CI, 3.73-41.48; p,0.0001) (Table 2) and
ICH (OR, 4.29; 95% CI, 1.32-13.91; p = 0.015) (Table 3) patients
after adjusting for variables with a proven biological relevance for
outcome. However, when molecular markers levels were included
in the logistic regression model, we observed that glutamate (OR,
1.01; 95% CI, 1.00-1.02; p = 0.001) and infarct volume (OR, 1.06;
95% CI, 1.01-1.10; p = 0.015) were the only variables indepen-
dently associated to poor outcome in IS, and active MMP-9 (OR,
1.04; 95% CI, 1.00-1.08; p = 0.002) and NIHSS at admission
(OR, 1.29; 95% CI, 1.13-1.49; p,0.0001) in ICH (Table 2 and
3).
Discussion
This study shows that body temperature within the first
24 hours $37.5uC predict poor outcome in both patients with
IS and ICH. These results are in line with the well-established
deleterious effect of hyperthermia in these neuronal pathologies
[6,7]. However, while IS patients with Tmax $37.5uC showed
higher levels of glutamate, ICH patients with Tmax $37.5uC
showed higher levels of active MMP-9. These clinical data seems
to indicate that in IS the deleterious effect of hyperthermia on
functional outcome could be mediated by glutamate and infarct
volume, in ICH is mediated mainly by active MMP-9 and
neurological deficit at admission. Therefore, although the poor
outcome associated to hyperthermia is similar in patients with IS
and ICH, the underlying mechanisms may be completely
different.
The results of this study show the critical role of glutamate in the
deleterious effect of hyperthermia during acute phase of IS. These
findings support our previous experimental data, where we have
showed that temperature effects are strongly associated to
glutamate excitotoxicity. In fact, analysis of the inflammatory
response and metabolic rate demonstrates that effects of hyper-
thermia on ischemic damage were also less critical than glutamate
excitotoxity [10]. In line with our previous study [10], our findings
strengthen the hypothesis that the beneficial effect of treatments
focused in the reduction of hyperthermia after ischemia, such as
hypothermia or antipyretic drugs, could be enhanced in combi-
nation with drugs able to reduce the glutamate excitotoxicity (see
[19] for review).
On the other hand, it has been widely described the relationship
between hyperthermia and poor functional outcome after ICH
[9,14,20]. However, the molecular mechanisms associated to the
deleterious effects of hyperthermia in ICH have not yet been fully
clarified. It has been suggested that molecular processes such as
inflammation, glutamate excitotoxicity, infections, and processes
in relation to the hematoma growth, which induces early
pathophysiologic changes in the surrounding brain tissue such as
breakdown of the brain-blood barrier (BBB) and development of
vasogenic edema, considered relevant predictors of poor outcome
in ICH, could be involved in the deleterious consequences of
hyperthermia [6,20]. In our study, we found that the association
between hyperthermia and poor outcome in ICH seems to be
mainly mediated by active MMP-9 (a biomarker of BBB
breakdown) and the baseline neurological deficit, but not by an
increase of glutamate levels as occurs in IS. Hematoma growth is
one of the main physiological complications associated to poor
outcome in ICH [14,20]. Although the precise mechanisms
involved in the deleterious effect of early hematoma growth during
the acute phase is also poorly understood, MMPs overexpression
and breakdown of the BBB are proposed as two of the most
important processes associated to hematoma growth [3]. Likewise,
MMP-9 seems to be also involved in secondary brain injury and
outcome after primary ICH in humans [21–23]. Therefore, the
results of this study suggest for first time that, over other
mechanisms, increase of active MMP-9 represents the one of the
most critical mechanism involve in the deleterious effect of
hypothermia in ICH. Therefore, it is tentative to postulate that the
management of hyperthermia in ICH patients should include
treatments able to reduce hematoma or MMP-9 activity. In this
regard, the use of treatments with antipyretics and/or cooling
blankets in combination with drugs against the hematoma
extension could help to reduce the deleterious effect of hyperther-
mia.
Interestingly, our results showed that glutamate excitotoxicity
does not seem to act as a critical mechanism involved in the
deleterious effect of hyperthermia in ICH as happens with
ischemia. Although experimental studies have demonstrated that
glutamate is transiently accumulated in the perihematoma region
during the early phase of ICH, the specific role of glutamate in the
brain injury observed after ICH needs to be further explored. In
this regard, in the current animal models (autologous blood or
collagenase injection) of ICH it is difficult to know if glutamate
increase is produced as result of the artificial effect of the tissue
disruption after blood or collagenase injection, or it is due to the
mass effect of perihematomal edema, which can cause a regional
hypoperfusion by mechanical compression of blood vessels [24].
Moreover, clinical studies have not even demonstrated the
relevance of glutamate in ICH. Therefore further experimental
and clinical studies are necessary to elucidate the role of glutamate
in ICH.
Due to hyperthermia is quite different from fever in several
fundamental aspects, including hypothalamic set point change in
fever but not in hyperthermia, we considered that one limitation
of the study was that patients with hyperthermia were not classified
in those with and without fever. Nevertheless, since body
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Table 1. Clinical, biochemical and neuroimaging characteristics of ischemic and hemorrhagic stroke patients according to the
cutoff of point of ,37.5uC or $37.5uC for the highest body temperature within the first 24 hours.
VARIABLES ISCHEMIC STROKE INTRACEREBRAL HEMORRHAGE
,37.56C $37.56C p ,37.56C $37.56C p
n = 50 n = 50 n = 50 n = 50
Age, years 71.9612.9 74.3611.7 0.412 70.5611.6 73.2611.9 0.133
Female, % 37.0 52.0 0.061 48.0 38.0 0.419
History of hypertension, % 64.0 66.0 0.841 60.0 68.0 0.546
History of diabetes, % 20.0 12.0 0.414 6.0 20.0 0.071
History of dyslipemia, % 18.0 14.0 0.786 30.0 20.0 0.356
Alcohol consumption, % 8.0 12.0 0.741 12.0 16.0 0.774
Smoking habit, % 10.0 20.0 0.262 2.0 4.0 0.554
History of peripheral vascular disease, % 2.0 8.0 0.362 0 6.0 0.242
History of ischemic heart disease, % 10.0 6.0 0.715 4.0 12.0 0.269
History of atrial fibrillation, % 14.0 22.0 0.436 10.0 12.0 0.749
History of heart failure, % 4.0 8.0 0.678 2.0 2.0 1.000
History of transient ischemic attack, % 4.0 2.0 0.558 0 0 -
Previous antiplatelets, % 30.0 16.0 0.153 20.0 12.0 0.414
Previous anticoagulants, % 2.0 14.0 0.059 6.0 4.0 0.646
Body temperature at admission,uC 36.360.4 36.560.5 0.092 36.560.4 36.760.9 0.115
Highest temperature within first 24 h,uC 36.460.5 37.960.2 ,0.0001 36.460.5 37.960.4 ,0.0001
Baseline systolic blood pressure, mm Hg 153.4627.5 150.6632.2 0.836 158.7625.7 157.3632.9 0.123
Baseline diastolic blood pressure, mm Hg 83.9615.9 81.6618.7 0.475 86.2616.4 80.7616.8 0.877
Glucose levels, mg/dL 128.6652.7 154.1671.4 0.015 124.1628.4 141.1649.7 0.070
Leukocytes, x103/mL 7.962.9 11.563.3 ,0.0001 8.762.5 9.563.5 0.102
Fibrinogen, mg/dL 456.56122.6 562.66133.2 ,0.0001 480.46100.4 516.96127.8 0.145
hs-CRP, mg/L 2.163.2 10.3610.7 ,0.0001 5.266.4 6.867.9 0.141
NIHSS at admission 9 [6,15] 11 [9,18] 0.069 9 [6,16] 12 [7,15] 0.111
Early neurological deterioration (END), % 2.0 10.0 0.092 2.0 26.0 ,0.0001
Infections during the first 72 hours, % 2.0 34.0 ,0.0001 2.0 30.0 ,0.0001
Ischemic stroke subtype 0.136 -
- Atherothrombotic, % 26.0 28.0 - -
- Cardioembolic, % 34.0 44.0 - -
- Lacunar, % 10.0 10.0 - -
- Undetermined, % 30.0 18.0 - -
Intracerebral hemorrhage subtype - 0.123
- Hypertensive, % - - 40.0 32.0
- Amyloid, % - - 22.0 26.0
- Antiplatelet/anticoagulant treatment, % - - 14.0 24.0
- Other, % - - 24.0 18.0
Thrombolytic treatment, % 8.0 8.0 1.000 - - -
Inclusion in clinical trial, % 6.0 6.0 1.000 0 0 -
DWI volume at admission, mL 41.4630.3 56.3654.8 0.553 - - -
Infarct volume at 4th-7th day, mL 16.8631.9 55.4657.6 ,0.0001 - - -
Infarct volume growth, % -72.8623.5 -3.6616.6 ,0.0001 - - -
ICH volume at admission, mL - - - 34.1621.7 51.9656.9 0.200
ICH volume at 4th-7th day, mL - - - 27.6622.4 68.5667.8 ,0.0001
ICH growth, % - - - -22.5623.0 52.3680.2 ,0.0001
Glutamate levels at admission, mM 118.56106.7 226.2697.3 ,0.0001 121.8686.9 137.6696.7 0.385
Active MMP-9 at admission, ng/mL 27.6612.3 28.8613.7 0.620 17.369.4 48.2614.4 ,0.0001
Modified Rankin Scale score at 3 months 1 [0, 3] 4 [3,6] ,0.0001 2 [0, 3] 3 [2,6] ,0.0001
doi:10.1371/journal.pone.0078429.t001
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temperature is the main variable but not the physiological
mechanism involved in the increase of temperature, we consider
that this limitation does not affect to the conclusions of our results.
In conclusion, the present study demonstrates that body
temperature within the first 24 hours $37.5uC predict poor
outcome in both IS and ICH patients, but the underlying
mechanisms are different, glutamate excitotoxicity and infarct
volume in IS and active MMP-9 and neurological deficit in case of
ICH. Therefore, future protective strategies focused on the
management of hyperthermia effects in both IS and ICH should
be design taking into account the mechanism involved.
Table 2. Adjusted OR of the Tmax $37.5uC within the first 24 hours and molecular markers levels for poor functional outcome at 3
months in ischemic stroke.
Independent variable Non-adjusted Adjusted
OR (95% CI) p OR (95% CI) p
Model without molecular markers
Age 1.02 (0.99 – 1.06) 0.154 1.00 (0.96 – 1.05) 0.912
History of atrial fibrillation 1.17 (0.41 – 3.32) 0.768 1.12 (0.26 – 5.37) 0.831
NIHSS at admission 1.16 (1.08 – 1.25) ,0.0001 1.07 (0.97 – 1.18) 0.150
Glucose levels at admission 1.00 (0.99 – 1.01) 0.316 1.00 (0.99 – 1.01) 0.903
DWI volume at admission 1.04 (1.01 – 1.06) 0.003 1.04 (1.00 – 1.08) 0.037
Tmax $37.56C within first 24 h 11.15 (4.26 – 29.18) ,0.0001 12.43 (3.73 – 41.48) ,0.0001
Model with molecular markers
Age 1.02 (0.99 – 1.06) 0.154 1.01 (0.95 – 1.07) 0.732
History of atrial fibrillation 1.17 (0.41 – 3.32) 0.768 2.05 (0.30 – 13.82) 0.462
NIHSS at admission 1.16 (1.08 – 1.25) ,0.0001 1.06 (0.94 – 1.19) 0.327
Glucose levels at admission 1.00 (0.99 – 1.01) 0.316 1.00 (0.99 – 1.02) 0.300
DWI volume at admission 1.04 (1.01 – 1.06) 0.003 1.06 (1.01 – 1.10) 0.015
Tmax $37.56C within first 24 h 11.15 (4.26 – 29.18) ,0.0001 4.95 (0.92 – 12.75) 0.061
Glutamate levels 1.01 (1.00 – 1.02) ,0.0001 1.01 (1.00 – 1.02) 0.001
Active MMP-9 levels 1.05 (1.02 – 1.09) 0.005 1.13 (0.94 – 1.23) 0.057
doi:10.1371/journal.pone.0078429.t002
Table 3. Adjusted OR of the Tmax $37.5uC within the first 24 hours and molecular markers levels for poor functional outcome at 3
months in intracerebral hemorrhage.
Independent variable Non-adjusted Adjusted
OR (95% CI) P OR (95% CI) p
Model without molecular markers
Age 1.03 (0.99 – 1.06) 0.123 0.98 (0.94 – 1.03) 0.462
Previous anticoagulants 2.95 (0.47 – 18.58) 0.248 1.00 (0.11 – 9.49) 1.006
History of hypertension 1.54 (0.67 – 3.58) 0.312 1.35 (0.44 – 4.16) 0.599
NIHSS at admission 1.32 (1.18 – 1.47) ,0.0001 1.28 (1.13 – 1.45) ,0.0001
ICH volume at admission 1.03 (1.01 – 1.05) 0.004 1.01 (0.98 – 1.03) 0.533
Tmax $37.56C within first 24 h 4.00 (1.65 – 9.71) 0.002 4.29 (1.32 – 13.91) 0.015
Model with molecular markers
Age 1.03 (0.99 – 1.06) 0.123 0.98 (0.93 – 1.03) 0.532
Previous anticoagulants 2.95 (0.47 – 18.58) 0.248 1.37 (0.14 – 13.12) 0.785
History of hypertension 1.54 (0.67 – 3.58) 0.312 1.30 (0.40 – 4.21) 0.658
NIHSS volume at admission 1.32 (1.18 – 1.47) ,0.0001 1.29 (1.13 – 1.49) ,0.0001
ICH volume at admission 1.03 (1.01 – 1.05) 0.004 1.01 (0.98 – 1.03) 0.432
Tmax $37.56C within first 24 h 4.00 (1.65 – 9.71) 0.002 1.73 (0.59 – 5.07) 0.314
Glutamate levels 1.00 (0.99 – 1.01) 0.276 0.99 (0.98 – 1.01) 0.423
Active MMP-9 levels 1.04 (1.01 – 1.07) 0.003 1.04 (1.00 – 1.08) 0.002
doi:10.1371/journal.pone.0078429.t003
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15. Leira R, Rodrı́guez-Yáñez M, Castellanos M, Blanco M, Nombela F, et al.
(2006) Hyperthermia is a surrogate marker of inflammation-mediated cause of
brain damage in acute ischaemic stroke. J Intern Med 260: 343–349.
16. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993)
Classification of subtype of acute ischemic stroke. Definitions for use in a
multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke
Treatment. Stroke 24: 35–41.
17. Sims JR, Gharai LR, Schaefer PW, Vangel M, Rosenthal ES, et al. (2009) ABC/
2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes.
Neurology 72: 2104–2110.
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